Skip to content
Easy Peptide Info
Menu
Investigational drug

What is cagrilintide?

Cagrilintide explained in plain English: what it is, what the research shows, side effects, legal status and dosage, plus a calculator for syringe units. Doses shown come only from the label or published trials, each with its source. Also called Cagri, CagriSema (with semaglutide).

Cagrilintide is an investigational drug: it is not approved by the FDA or any other regulator yet. This page is educational; talk with a qualified healthcare professional.

Calculate
Vial unit

= 5,000 mcg

mL
Dose unit
Syringe type
Syringe size

Units to draw

–units

Enter your dose.

Syringe, no result yetU-100, 1 mL syringe holding up to 100 units. Enter your dose.0102030405060708090100

Saved calculations

No saved calculations yet. Save one from the results.

What is cagrilintide?

Cagrilintide is an investigational weight-loss peptide made by Novo Nordisk. It is a long-acting copy of amylin, a hormone the pancreas releases along with insulin after meals.

On its own it is still experimental. It is being developed mainly in combination with semaglutide as a weekly injection called CagriSema.

How does cagrilintide work?

Cagrilintide switches on amylin receptors, which slow how fast the stomach empties and tell the brain you’re full. Semaglutide works on a different pathway (GLP-1), so combining them reduces appetite more than either alone.

What do the cagrilintide trials show?

In the REDEFINE 1 trial, adults with obesity on CagriSema lost about 20% of their body weight on average, compared with about 15% on semaglutide alone. About 92% lost at least 5% of their weight.

Cagrilintide alone has produced more modest weight loss in earlier trials.

Cagrilintide side effects

The main side effects are stomach-related: nausea, vomiting, diarrhea and constipation, mostly while the dose is being raised. Its long-term risks aren’t fully known because it isn’t approved yet.

Cagrilintide is not approved by the FDA or any other regulator, so it is only legally available in clinical trials. Novo Nordisk submitted CagriSema to the FDA in December 2025, with a decision expected in late 2026.

Products sold online as “cagrilintide” are unapproved research chemicals, and nobody checks what’s in them.

How do you reconstitute cagrilintide?

In trials, CagriSema comes ready to use in a pen. If you have a powder vial, the calculator above turns the vial size, the bacteriostatic water and a dose into syringe units, and the reconstitution guide explains each step.

See the dosage section below for what is known about doses, with sources.

Cagrilintide dosage in clinical trials

Cagrilintide is not approved. In the REDEFINE 1 trial, CagriSema combined cagrilintide and semaglutide once a week, reached after a gradual step-up.

Doses tested in published clinical trials. They are not approved doses, and trial participants were closely monitored.

Cagrilintide doses, with sources
WhenDoseHow often
REDEFINE 1, CagriSema target dose2.4 mg cagrilintide + 2.4 mg semaglutide[1]Once a week
REDEFINE 1, cagrilintide alone (comparison group)2.4 mg[1]Once a week
  1. REDEFINE 1 trial (2025), Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity, NEJM

Medical disclaimer: this dosage information is for education only and comes from the source shown for each row. It is not medical advice and not a recommendation for you. Only a licensed prescriber who knows your health can decide whether Cagrilintide is right for you and at what dose. Don't start, change or stop a medicine based on this page, and don't use research peptides or unapproved drugs based on trial doses.

Cagrilintide concentration chart

The concentration of a Cagrilintide vial depends only on its size and the water you add. Each unit on a U-100 syringe holds one hundredth of a mL.

Cagrilintide concentration by vial size and water
Vial + waterConcentrationPer unit (U-100)
5 mg + 1 mL5,000 mcg/mL (5 mg/mL)50 mcg per unit (0.05 mg per unit)
5 mg + 2 mL2,500 mcg/mL (2.5 mg/mL)25 mcg per unit (0.025 mg per unit)
5 mg + 3 mL1,666.67 mcg/mL (1.66667 mg/mL)16.67 mcg per unit (0.01667 mg per unit)
10 mg + 1 mL10,000 mcg/mL (10 mg/mL)100 mcg per unit (0.1 mg per unit)
10 mg + 2 mL5,000 mcg/mL (5 mg/mL)50 mcg per unit (0.05 mg per unit)
10 mg + 3 mL3,333.33 mcg/mL (3.33333 mg/mL)33.33 mcg per unit (0.03333 mg per unit)

Frequently asked questions

What is CagriSema?

CagriSema is a weekly injection that combines cagrilintide with semaglutide. Novo Nordisk submitted it to the FDA in December 2025, and a decision is expected in late 2026.

How much weight do people lose on CagriSema?

In the REDEFINE 1 trial, people on CagriSema lost an average of about 20% of their body weight, compared with about 15% on semaglutide alone.

What is amylin?

Amylin is a hormone released with insulin after meals. It slows stomach emptying and signals fullness to the brain.

Sources

  1. Pharmaceutical Executive (2025), Novo Nordisk Submits NDA to FDA for CagriSema
  2. Drugs.com, CagriSema approval history

Last updated .

More peptide guides and calculators